Keytruda is an immunotherapy drug that is prescribed to cancer patients and is used to treat different types of cancer. It was first approved by the FDA in 2014 for the treatment of advanced or ...
The Food and Drug Administration (FDA) recently approved Keytruda (pembrolizumab) plus chemoradiotherapy (CRT) for the treatment of patients with stages 3 to 4A cervical cancer. The first approval of ...
Keytruda is a prescription drug that’s given as an intravenous (IV) infusion (and injection into a vein over a period of time). Learn about how the drug is given, how often you’ll receive doses, and ...
Keytruda is an immunotherapy drug that is used to treat different types of cancers. The drug helps the body's own immune system to fight the cancer cells. Developed and sold by Merck & Co., the drug ...
Read all the latest news headline updates on cancer drugs. Get all the cancer drugs breaking news updates, videos, photostories and more at Business Standard.
Keytruda, known scientifically as pembrolizumab, is an immunotherapy drug that has transformed cancer treatment for many patients worldwide. Traditional chemotherapy works by directly attacking the ...
EU CHMP recommends approval of Merck’s Keytruda plus Padcev as perioperative treatment for adults with cisplatin-ineligible resectable muscle-invasive bladder cancer: Rahway, Ne ...
Merck (NYSE:MRK) is expanding clinical work around KEYTRUDA through a new collaboration with Erasca on ERAS-0015 in RAS-mutant solid tumors. Merck and Inhibrx reported positive interim Phase 2 data ...
Subcutaneous Keytruda plus chemotherapy met pharmacokinetic endpoints, showing noninferiority to the intravenous formulation in metastatic NSCLC treatment. The subcutaneous formulation, administered ...
This synergistic rationale drove the two-part structure of Toragen’s Phase 1 trial, with monotherapy in Part 1 and ...
Merck hasn’t had much luck pairing cancer superstar Keytruda with PARP inhibitor Lynparza. But after flunking three clinical trials with the combination, the company has emerged with a tepid win with ...
Korea approves Keytruda SC, slashing treatment time to 2 minutes Alteogens ALT-B4 enables faster subcutaneous Keytruda launch ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results